open access

Vol 25, No 1 (2019)
Articles
Published online: 2019-03-20
Get Citation

The place of heparins in the treatment of venous thromboembolism

Andrzej Wojtak, Tomasz Zubilewicz
DOI: 10.5603/AA.2019.0006
·
Acta Angiologica 2019;25(1):35-40.

open access

Vol 25, No 1 (2019)
Articles
Published online: 2019-03-20

Abstract

Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication
that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing
population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively
acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered
low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.

Abstract

Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication
that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing
population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively
acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered
low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.

Get Citation

Keywords

venous thromboembolism, low-molecular-weight heparin, enoxaparin, deep vein thrombosis, pulmonary embolism

About this article
Title

The place of heparins in the treatment of venous thromboembolism

Journal

Acta Angiologica

Issue

Vol 25, No 1 (2019)

Pages

35-40

Published online

2019-03-20

DOI

10.5603/AA.2019.0006

Bibliographic record

Acta Angiologica 2019;25(1):35-40.

Keywords

venous thromboembolism
low-molecular-weight heparin
enoxaparin
deep vein thrombosis
pulmonary embolism

Authors

Andrzej Wojtak
Tomasz Zubilewicz

References (39)
  1. Praca zbiorowa. Polskie Wytyczne Profilaktyki i Leczenia Żylnej Choroby Zakrzepowo-Zatorowej. Medycyna Praktyczna. Wyd. specjalne. 2012.
  2. Robertson L, Kesteven P, McCaslin JE, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2015(6): CD010956.
  3. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007; 167(9): 935–943.
  4. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160(6): 761–768.
  5. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2): 199–205.
  6. Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(9): 832.e13–832.e21.
  7. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e419S–e496S.
  8. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13): 1227–1235.
  9. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e351S–e418S.
  10. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8(11): 2450–2457.
  11. van der Hulle T, Cheung WY, Kooij S, et al. YEARS study group. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017; 390(10091): 289–297.
  12. Zawilska K, Jaeschke R, Tomkowski W, et al. Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Medycyna Praktyczna, Wyd. specjalne. 2009; 1: 1–55.
  13. National Institute for Health and Care Excellence. CG92: Venous thromboembolism— reducing the risk. 2010. http://guidance.nice.org.uk/CG92 (1.05.2014).
  14. Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol. 2012; 87 Suppl 1: S133–S136.
  15. Hass B, Pooley J, Harrington AE, et al. Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J. 2012; 10(1): 24.
  16. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e44S–e88S.
  17. Charakterystyka produktu leczniczego Neoparin. http://www.urpl.gov.pl/pl.
  18. Samama MM, Desnoyers PC. Low molecular weight heparins: an overview. Thrombosis, Scientic and Clinical Prospectives. 1995; 5: 95–106.
  19. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144(9): 673–684.
  20. Szczeklik A. Choroby wewnętrzne. Kompendium medycyny praktycznej 2010. Wydanie II zaktualizowane i rozszerzone. Medycyna Praktyczna, Kraków 2010.
  21. Qaseem A, Snow V, Barry P, et al. Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism, Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med. 2007; 5(1): 57–62.
  22. Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011; 9: 120–38.
  23. Coppola R, Mari D, Lattuada A, et al. Von Willebrand factor in Italian centenarians. Haematologica. 2003; 88(1): 39–43.
  24. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002; 28(6): 555–568.
  25. Melis F, Vandenbrouke JP, Büller HR, et al. Estimates of risk of venous thrombosis during pregnancy and puerperium are not influenced by diagnostic suspicion and referral basis. Am J Obstet Gynecol. 2004; 191(3): 825–829.
  26. Cunningham FG, Leveno KL, Bloom SL. Thromboembolic disorders. In: Cunningham FG, Leveno KL, Bloom SL. ed. Williams obstetrics. McGraw & Hill, New York 2005.
  27. Sajdak S, Rybak Z, Oszkinis G. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej w ciąży. Przeg. Gin. Poł. 2006; 6(4): 205–216.
  28. McLintock C. Anticoagulant choices in pregnant women with mechanical heart valves: Balancing maternal and fetal risks – the difference the dose makes. Thrombosis Research. 2013; 131: S8–S10.
  29. Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33(6): 1637–1641.
  30. Trojnarska O, Plaskota K. Leczenie przeciwkrzepliwe w czasie ciąży u kobiet z implantowanymi protezami zastawkowymi. Kardiol Pol. 2012; 70: 622–626.
  31. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27(29): 4821–4826.
  32. Lee A.Y. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am. Soc. Hematol. Educ. Program 2010: 144–149.J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, H.J. Schunemann American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition): Antithrombotic and Thrombolytic Therapy 8th Ed: ACCP Guidelines Chest, 133 (2008), 71-105 2008.
  33. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
  34. Wojtukiewicz M, Sierko E, Tomkowski W, et al. Wytyczne dotyczące profilaktyki i leczenia żylnej choroby zakrzepowo- -zatorowej u chorych na nowotwory poddawanych leczeniu zachowawczemu. Onkologia w praktyce klinicznej — edukacja. 2006; 2: 73–101.
  35. Zawilska K, Zawilska K. Praktyczne aspekty leczenia żylnej choroby zakrzepowo-zatorowej. Hematologia. 2017; 7(3): 231–242.
  36. Ageno W, Beyer-Westendorf J, Garcia DA, et al. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016; 41(1): 129–143.
  37. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e326S–e350S.
  38. Spyropoulos AC, Turpie AGG, Dunn AS, et al. REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006; 4(6): 1246–1252.
  39. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl